← All trials
NCT06205849
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 25, 2024
- Primary completion
- Aug 31, 2027
- Completion date
- Aug 31, 2029
- First posted
- Jan 16, 2024
- Last posted
- Jun 28, 2024
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San DiegoLead sponsor
- University of California, San DiegoSponsor investigator
- University of California, Los AngelesCollaborator
- National Cancer Institute (NCI)Collaborator
- University of California, San DiegoOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.